Clicca qui per scaricare

The cross-talk between peripheral and central infl ammation in depression and the potential for anti-infl ammatory treatments
Titolo Rivista: PNEI REVIEW 
Autori/Curatori: Maria Antonietta Nettis, Valeria Mondelli 
Anno di pubblicazione:  2018 Fascicolo: 2 Mente, cervello e salute Lingua: Inglese 
Numero pagine:  12 P. 60-71 Dimensione file:  1113 KB
DOI:  10.3280/PNEI2018-002005
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più:  clicca qui   qui 

Growing evidence suggests that inflammation may be the biological pathway linking physical and psychiatric disorders, such as depression. This evidence has led to the investigation of the antidepressant effect of anti-inflammatory agents, as add-on treatment or as monotherapy. This article reviews the literature about the role of inflammation in depression, with a particular focus on the communication between the peripheral and the central immune system, the role of brain microglia and the blood-brain barrier. In the second part of this manuscript, the Authors review the current evidence on the use of antiinflammatory treatments in depression. The paper concludes by highlighting the unresolved questions and challenges for future studies, such as the need of in vivo models of the link between peripheral and central inflammation and the identification of subgroups of patients with depression that would benefit from anti-inflammatory treatments.

Un numero crescente di studi ha evidenziato il possibile ruolo dell’infiammazione nell’associazione tra disturbi della salute fisica e depressione maggiore. Queste evidenze hanno portato ad un aumentato interesse sul potenziale ruolo antidepressivo di agenti anti-infiammatori, sia in monoterapia che come add-on. Questo articolo propone una revisione della letteratura sull’associazione tra infiammazione e depressione, concentrandosi in particolare sui meccanismi di comunicazione tra il sistema immunitario periferico e quello centrale, sul ruolo della microglia cerebrale e della barriera emato-encefalica. Nella seconda parte del manoscritto, gli Autori si concentrano sulla revisione degli studi clinici che hanno indagato l’effetto di diversi farmaci anti-infiammatori in pazienti con depressione maggiore. L’articolo conclude sollevando l’attenzione su una serie di domande ancora irrisolte e, in particolare, sulla necessità di modelli in vivo della comunicazione tra infiammazione periferica e centrale e l’identificazione dei pazienti depressi che potrebbero maggiormente beneficiare da un trattamento con farmaci anti-infiammatori.
Keywords: Infiammazione, Depressione, Microglia, Anti-infiammatori, Minociclina, Barriera emato-encefalica.

  1. Miller A.H. and Raison C.L. (2016). The role of infl ammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol., 16(1): 22-34.
  2. Mondelli V., Vernon A.C., Turkheimer F., Dazzan P. and Pariante C.M. (2017). Brain microglia in psychiatric disorders. Lancet Psychiatry, 4(7): 563-572., DOI: 10.1016/S2215-0366(17)30101-
  3. Pae C.U., Marks D.M., Han C. and Patkar A.A. (2008). Does minocycline have antidepressant effect?. Biomed Pharmacother., 62(5): 308-311.
  4. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E. and Miller A.H. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infl iximab for treatment-resistant depression: the role of baseline infl ammatory biomarkers. JAMA Psychiatry, 70(1): 31-41.
  5. Rosenblat J.D. and McIntyre R.S. (2018). Effi cacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. J. Affect. Disord., 227: 219-225.
  6. Sandiego C.M., Gallezot J.D., Pittman B., Nabulsi N., Lim K., Lin S.F., Matuskey D., Lee J.Y., O’Connor K.C., Huang Y., Carson R.E., Hannestad J. and Cosgrove K.P. (2015). Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. PNAS, 112(40): 12468-12473.
  7. Setiawan E., Wilson A.A., Mizrahi R., Rusjan P.M., Miler L., Rajkowska G., Suridjan I., Kennedy J.L., Rekkas P.V., Houle S. and Meyer J.H. (2015). Role of translocator protein density, a marker of neuroinfl ammation, in the brain during major depressive episodes. JAMA Psychiatry, 72(3): 268-275.
  8. Setiawan E., Attwells S., Wilson A.A., Mizrahi R., Rusjan P.M., Miler L., Xu C., Sharma S., Kish S., Houle S. and Meyer, J.H. (2018). Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry, 5(4): 339-347., DOI: 10.1016/S2215-0366(18)30048-
  9. Solomon S.D., Wittes J., Finn P.V., Fowler R., Viner J., Bertagnolli M.M., Arber N., Levin B., Meinert C.L., Martin B., Pater J.L., Goss P.E., Lance P., Obara S., Chew E.Y., Kim J., Arndt G. and Hawk E. (2008). Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation, 117(16): 2104-2113., DOI: 10.1161/CIRCULATIONAHA.108.764530
  10. Su L., Faluyi Y.O., Hong Y.T., Fryer, T.D., Mak E., Gabel S., Hayes L., Soteriades S., Williams G.B., Arnold, R., Passamonti L., Rodriguez P.V., Surendranathan A., Bevan-Jones R.W., Coles J., Aigbirhio F., Rowe J.B. and O’Brien, J.T. (2016). Neuroinfl ammatory and morphological changes in late-life depression: the NIMROD study. Br. J. Psychiatry, 209(6): 525-526.
  11. Torres-Platas S.G., Cruceanu C., Chen G.G., Turecki G. and Mechawar N. (2014). Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav. Immun., 42: 50-59.
  12. Walker F.R., Beynon S.B., Jones K.A., Zhao Z., Kongsui R., Cairns M. and Nilsson M. (2014). Dynamic structural remodelling of microglia in health and disease: a review of the models, the signals and the mechanisms. Brain Behav. Immun., 37: 1-14.
  13. Zheng L.S., Kaneko N. and Sawamoto K. (2015). Minocycline treatment ameliorates interferon-alpha- induced neurogenic defects and depression-like behaviors in mice. Front. Cell. Neurosci., 9: 5.
  14. Abbasi S.H., Hosseini F., Modabbernia A., Ashrafi M. and Akhondzadeh S. (2012). Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J. Affect. Disord., 141(2-3): 308-314.
  15. Arana G.W., Santos A.B., Laraia M.T., McLeod-Bryant S., Beale M.D., Rames L.J., Roberts J.M., Dias J.K. and Molloy M. (1995). Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am. J. Psychiatry, 152(2): 265-267.
  16. Baumeister D., Akhtar R., Ciufolini S., Pariante C.M. and Mondelli V. (2016). Childhood trauma and adulthood infl ammation: a meta-analysis of peripheral C reactive protein, interleukin-6 and tumour necrosis factor-α. Mol. Psychiatry, 21(5): 642-649.
  17. Baumeister D., Russell A., Pariante C.M. and Mondelli V. (2014). Infl amatory biomarker profi les of mental disorders and their relation to clinical, social and lifestyle factors. Soc. Psychiatry Psychiatr. Epidemiol., 49(6): 841-849.
  18. Bender D.A. and McCreanor G.M. (1985). Kynurenine hydroxylase: a potential ratelimiting enzyme in tryptophan metabolism. Biochem. Soc. Trans., 13(2): 441-443.
  19. Benros M.E., Waltoft B.L., Nordentoft M., Ostergaard S.D., Eaton W.W., Krogh J. and Mortensen P.B. (2013). Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry, 70(8): 812-820.
  20. Bentivoglio M., Mariotti R. and Bertini G. (2011). Neuroinfl ammation and brain infections: historical context and current perspectives. Brain Res. Rev., 66(1-2): 152-173.
  21. Block M.L., Zecca L. and Hong J.S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci., 8(1): 57-69.
  22. Burke N.N., Kerr D.M., Moriarty O., Finn D.P. and Roche M. (2014). Minocycline modulates neuropathic pain behaviour and cortical M1-M2 microglial gene expression in a rat model of depression. Brain Behav. Immun., 42: 147-156.
  23. Calcia M.A., Bonsall D.R., Bloomfi eld P.S., Selvaraj S., Barichello T. and Howes O.D. (2016). Stress and neuroinfl ammation: a systematic review of the effects of stress on microglia and the implications for mental illness. Psychopharmacology (Berl), 233(9): 1637-1650.
  24. Cheng Y., Desse S., Martinez A., Worthen R.J., Jope R.S. and Beurel, E. (2018). TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. Brain Behav. Immun., 69: 556-567.
  25. Dantzer R., O’Connor J.C., Freund G.G., Johnson R.W. and Kelley, K.W. (2008). From infl ammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci., 9(1): 46-56.
  26. DeBattista C., Posener J.A., Kalehzan B.M. and Schatzberg A.F. (2000). Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebocontrolled study. Am. J. Psychiatry, 157(8): 1334-1337.
  27. Dickens C., McGowan L., Clark-Carter D. and Creed F. (2002). Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom. Med., 64(1): 52-60.
  28. Felger J.C. and Miller A.H. (2012). Cytokine effects on the basal ganglia and dopamine function: the subcortical source of infl ammatory malaise. Front. Neuroendocrinol., 33(3): 315-327.
  29. Fields C., Drye L., Vaidya V. and Lyketsos C. (2012). Celecoxib or naproxen treatment does not benefi t depressive symptoms in persons age 70 and older: fi ndings from a randomized controlled trial. Am. J. Geriatr. Psychiatry, 20(6): 505-513.
  30. Friebe A., Horn M., Schmidt F., Janssen G., Schmid-Wendtner M.H., Volkenandt M., Hauschild A., Goldsmith C.H. and Schaefer M. (2010). Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics, 51(6): 466-473.
  31. Grosse L., Ambree O., Jorgens S., Jawahar M.C., Singhal G., Stacey D., Arolt V. and Baune B.T. (2016). Cytokine levels in major depression are related to childhood trauma but not to recent stressors. Psychoneuroendocrinology, 73: 24-31.
  32. Hannestad J., DellaGioia N., Gallezot J.D., Lim K., Nabulsi N., Esterlis I., Pittman B., Lee J.Y., O’Connor K.C., Pelletier D. and Carson R.E. (2013). The neuroinfl ammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C]PBR28 PET study. Brain Behav. Immun., 33: 131-138. bbi.2013.06.010
  33. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., Sheridan J.F. and Godbout J.P. (2008). Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinfl ammation, sickness behavior, and anhedonia. J. Neuroinfl ammation, 5: 15., DOI: 10.1186/1742-2094-5-1
  34. Hinwood M., Tynan R.J., Charnley J.L., Beynon S.B., Day T.A. and Walker F.R. (2013). Chronic stress induced remodeling of the prefrontal cortex: structural re-organization of microglia and the inhibitory effect of minocycline. Cereb. Cortex, 23(8): 1784-1797.
  35. Holmes S.E., Hinz R., Conen S., Gregory C.J., Matthews J.C., Anton-Rodriguez J.M., Gerhard A. and Talbot P.S. (2018). Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Infl ammation in Suicidal Thinking: A Positron Emission Tomography Study. Biol. Psychiatry, 83(1): 61-69.
  36. Iyengar R.L., Gandhi S., Aneja A., Thorpe K., Razzouk L., Greenberg J., Mosovich S. and Farkouh M.E. (2013). NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am. J. Med., 126(11): 1017.e11-18.
  37. Kohler O., Krogh J., Mors O. and Benros M.E. (2016). Infl ammation in Depression and the Potential for Anti-Infl ammatory Treatment. Curr. Neuropharmacol., 14(7): 732-742., DOI: 10.2174/1570159X1466615120811370
  38. Korczak D.J., Pereira S., Koulajian K., Matejcek A. and Giacca A. (2011). Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link. Diabetologia, 54(10): 2483-2493.
  39. Li H., Sagar A.P. and Keri S. (2018). Translocator protein (18kDa TSPO) binding, a marker of microglia, is reduced in major depression during cognitive-behavioral therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 83: 1-7.
  40. Madeeh Hashmi A., Awais Aftab M., Mazhar N., Umair M. and Butt Z. (2013). The fi ery landscape of depression: A review of the infl ammatory hypothesis. Pak. J. Med. Sci., 29(3): 877-884.
  41. Martins J.G., Bentsen H. and Puri B.K. (2012). Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with effi cacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol. Psychiatry, 17(12): 1144-1149; discussion 1163-1147.
  42. Menard C., Pfau M.L., Hodes G.E., Kana V., Wang V.X., Bouchard S., Takahashi A., Flanigan M.E., Aleyasin H., LeClair K.B., Janssen W.G., Labonte B., Parise E.M., Lorsch Z.S., Golden S.A., Heshmati M., Tamminga C., Turecki G., Campbell M., Fayad Z.A., Tang C.Y., Merad M. and Russo S.J. (2017). Social stress induces neurovascular pathology promoting depression. Nat. Neurosci., 20(12): 1752-1760.

Maria Antonietta Nettis, Valeria Mondelli, Il cross-talk fra infi ammazione periferica e centrale nella depressione e i potenziali trattamenti anti-infi ammatori in "PNEI REVIEW" 2/2018, pp. 60-71, DOI:10.3280/PNEI2018-002005


FrancoAngeli è membro della Publishers International Linking Association associazione indipendente e no profit per facilitare l'accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche